Drug General Information (ID: DDIBGDP9F3)
Drug Name			Eptifibatide		Drug Info		Flurbiprofen		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Anticoagulants				Antiinflammatory Agents
Structure

Mechanism of Eptifibatide-Flurbiprofen Interaction (Severity Level: Moderate)
Increased risk of bleeding Click to Show/Hide Mechanism Graph
Drug Name		Eptifibatide				Flurbiprofen
Mechanism		Risk of bleeding Antiplatelet				Risk of bleeding Antiplatelet effects
Key Mechanism Factor 1
		Factor Name		Bleeding
		Factor Description		Patients may be at risk for bleeding when the outcome of a disease or disease treatment confounds the standard mechanisms for maintaining hemostasis. Signs or symptoms of abnormal bleeding include: bleeding that takes a long time to stop (including nosebleeds, bleeding gums, bleeding from cuts and abrasions, and menstrual bleeding); severe unexplained bruising, or bruising that becomes larger; blood in the urine or stool, etc.
Mechanism Description		Increased risk of bleeding by the combination of Eptifibatide and Flurbiprofen

Recommended Action
Management		It is recommended that these drugs be used together only when indicated by skilled personnel who are qualified and equipped to detect and treat bleeding complications.

References
1	Product Information. Integrilin (eptifibatide). Schering Laboratories, Kenilworth, NJ.
2	Product Information. ReoPro (abciximab). Lilly, Eli and Company, Indianapolis, IN.